Phase II study of mitomycin C and cisplatin in heavily pretreated advanced breast cancer

Autor: Zhonghua Wang, Xichun Hu, Xiangjin Liu, Jin Li, Xinmiao Yang, Haiyi Guo, Xinmin Zhao
Rok vydání: 2006
Předmět:
Zdroj: The Chinese-German Journal of Clinical Oncology. 5:442-445
ISSN: 1613-9089
1610-1979
DOI: 10.1007/s10330-006-0526-6
Popis: The mitomycin C and cisplatin combination was investigated in patients with advanced breast cancer who had been exposed to anthracyclines, vinorelbine and taxanes. Three-weekly regimen consisted of mitomycin, 6 mg/m2 administered intravenously on day 1, and cisplatin, 25 mg/m2 intravenously on day 1–3. Thirty-eight patients aged 25–75 years (median, 46 years) were treated with an overall response rate of 31.6%. The median time to progression (TTP) was 4.0 months. Median TTP for 12 patients with a complete or partial response was 9.0 months, while stable disease and progression of disease 4.0 months, P=0.002. Grade 3/4 side effects of neutropenia, thrombocytopenia and nausea/vomiting were documented in 4 (10.5%), 4 (10.5%) and 3 (7.9%) patients, respectively. The median overall survival was 13+ months. Mitomycin C/cisplatin doublet showed antitumor activity for anthracycline-, vinorelbine-and taxane-resistant breast cancer comparable to other regimens. This well-tolerated regimen provides an affordable option for patients in China.
Databáze: OpenAIRE
Externí odkaz: